Stoke Therapeutics, Inc. (STOK)
- Previous Close
11.66 - Open
11.41 - Bid 11.59 x 100
- Ask 11.72 x 400
- Day's Range
11.11 - 11.82 - 52 Week Range
3.35 - 16.40 - Volume
507,869 - Avg. Volume
1,215,509 - Market Cap (intraday)
609.254M - Beta (5Y Monthly) 0.76
- PE Ratio (TTM)
-- - EPS (TTM)
-2.39 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.67
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
www.stoketherapeutics.comRecent News: STOK
Performance Overview: STOK
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STOK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STOK
Valuation Measures
Market Cap
609.25M
Enterprise Value
409.92M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
58.58
Price/Book (mrq)
3.82
Enterprise Value/Revenue
46.69
Enterprise Value/EBITDA
-3.65
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.62%
Return on Equity (ttm)
-60.80%
Revenue (ttm)
8.78M
Net Income Avi to Common (ttm)
-104.7M
Diluted EPS (ttm)
-2.39
Balance Sheet and Cash Flow
Total Cash (mrq)
201.39M
Total Debt/Equity (mrq)
4.28%
Levered Free Cash Flow (ttm)
-45.07M